Related Experiment Video
Updated: Apr 18, 2026

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
[Effect of Shexiang Baoxin pill on coronary vasodilation by analysis of coronary angiography]
Insights
Shexiang Baoxin Pill (SBP) effectively dilates coronary arteries in patients with normal or stenotic coronary angiography (CAG) findings. This traditional Chinese medicine treatment does not significantly affect heart rate or blood pressure.
Area of Science:
- Cardiology
- Pharmacology
- Traditional Chinese Medicine
Background:
- Coronary artery disease (CAD) remains a leading cause of mortality worldwide.
- Vasodilation is a critical factor in improving coronary blood flow.
- Shexiang Baoxin Pill (SBP) is a traditional Chinese medicine used for cardiovascular conditions.
Purpose of the Study:
- To investigate the effect of Shexiang Baoxin Pill (SBP) on coronary vasodilation.
- To analyze changes in coronary artery diameter using coronary angiography (CAG).
Main Methods:
- A randomized controlled trial involving 300 patients undergoing CAG.
- Patients received either SBP or placebo sublingually before CAG.
- Quantitative angiography analysis measured coronary artery diameters before and after administration.
Main Results:
- SBP significantly increased coronary artery diameter in both normal and stenotic arteries (P < 0.01).
- No significant changes in heart rate, systolic, or diastolic blood pressure were observed.
- SBP demonstrated superior vasodilation compared to placebo (P < 0.05, P < 0.01).
Conclusions:
- Shexiang Baoxin Pill (SBP) effectively induces coronary vasodilation.
- SBP is safe for cardiovascular function, showing no adverse effects on heart rate or blood pressure.
- SBP shows potential as a therapeutic agent for improving coronary blood flow.
Objective:
To evaluate the effect of Shexiang Baoxin Pill (SBP) on coronary vasodilation by analysis of coronary angiography (CAG).
Methods:
A consecutive cohort of 300 patients who underwent CAG between January 2013 and July 2013 were recruited and randomly assigned to 2 groups before operation. Patients in the SBP group sublingually took SBP, while those in the control group sublingually took placebos. All patients repeatedly underwent CAG 5 min after administration. The vascular diameter was calculated by quantitative angiography analysis method. The diameter of the left anterior descending coronary artery was measured in patients whose coronary arteries had no stenosis. The narrowest vascular diameter was measured in patients whose coronary arteries had stenosis. The heart rate, blood pressure, and the vascular diameter were compared between before and after administration in the two groups.
Results:
In the two groups, there was no significant difference in changes of heart rate, systolic pressure, or diastolic pressure between before and after administration (all P > 0.05). There were 64 patients with normal CAG in the two groups, 30 in the control group and 34 in the SBP group. CAG showed there were 236 patients with stenotic coronary artery, 110 in the control group and 126 in the SBP group. The vascular diameter was obviously larger in patients in the SBP group with normal or abnormal CAG after administration (all P < 0.01). It was also obviously larger than that of the control group after administration (P < 0.05, P < 0.01).
Conclusion:
SBP could dilate both normal coronary artery and lesioned coronary arteries, but did not lead to fastened heart rate and decreased blood pressure.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antihypertensive Drugs: Vasodilators
Acute Coronary Syndrome III: Diagnostic Studies
Angina IV: Management

